Evidence map›Paper›PMID 36980828›Full record

ArticleGenes2023

Cellular Transcriptomics of Carboplatin Resistance in a Metastatic Canine Osteosarcoma Cell Line.

McKaela A Hodge, Tasha Miller, Marcus A Weinman, Brandan Wustefeld-Janssens, Shay Bracha, Brian W Davis

Open access · goldFull text read
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

McKaela A HodgeDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Science, Texas A&M University, College Station, TX 77840, USA.ORCID 0000-0001-9182-3771
Tasha MillerDepartment of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Science, Texas A&M University, College Station, TX 77840, USA.
Marcus A WeinmanDepartment of Cellular, Molecular and Biomedical Sciences, The University of Vermont, Burlington, VT 05405, USA.ORCID 0000-0002-2736-5005
Brandan Wustefeld-JanssensDepartment of Clinical Sciences, College of Veterinary Medicine Flint Animal Cancer Center, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-8458-1735
Shay BrachaDepartment of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-0406-2079
Brian W DavisDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Science, Texas A&M University, College Station, TX 77840, USA.ORCID 0000-0002-6121-135X
Texas A&M University · USColorado State University · USThe Ohio State University · USUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma prognosis has remained unchanged for the past three decades. In both humans and canines, treatment is limited to excision, radiation, and chemotherapy. Chemoresistance is the primary cause of treatment failure, and the trajectory of tumor evolution while under selective pressure from treatment is thought to be the major contributing factor in both species. We sought to understand the nature of platinum-based chemotherapy resistance by investigating cells that were subjected to repeated treatment and recovery cycles with increased carboplatin concentrations. Three HMPOS-derived cell lines, two resistant and one naïve, underwent single-cell RNA sequencing to examine transcriptomic perturbation and identify pathways leading to resistance and phenotypic changes. We identified the mechanisms of acquired chemoresistance and inferred the induced cellular trajectory that evolved with repeated exposure. The gene expression patterns indicated that acquired chemoresistance was strongly associated with a process similar to epithelial-mesenchymal transition (EMT), a phenomenon associated with the acquisition of migratory and invasive properties associated with metastatic disease. We conclude that the observed trajectory of tumor adaptability is directly correlated with chemoresistance and the phase of the EMT-like phenotype is directly affected by the level of chemoresistance. We infer that the EMT-like phenotype is a critical component of tumor evolution under treatment pressure and is vital to understanding the mechanisms of chemoresistance and to improving osteosarcoma prognosis.

Indexed as

Bone NeoplasmsOsteosarcomaAnimalsCarboplatinCell Line, TumorDogsDrug Resistance, NeoplasmHumansTranscriptomeCarboplatinchemoresistanceEMTosteosarcomatumor microenvironmenttumor trajectory

Identifiers

PMID36980828
PMCPMC10048144
OpenAlexW4321596643

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read30
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.